Skip to main content
Premium Trial:

Request an Annual Quote

John Linnan Jumps from ABI to Agencourt; May Van Promoted to VP at Agilent; Mark Schwartz Goes to Bayhill Therapeutics; and Others

NEW YORK (GenomeWeb News), April 21 - John Linnan has been appointed vice president of sales at Agencourt Bioscience, the Beverly, Mass. company said today.

 

Linnan comes to Agencourt from Applied Biosystems, where he most recently worked as district sales manager for New England. Prior to holding this position, Linnan was the regional sales manager for New England, mid-Atlantic, and Eastern Canada for Perspective Biosystems of Hertford, UK. He has also worked at Abbott Diagnostics in various sales positions. He has a BA in marketing and management from James Madison University.


 

Andrew DePristo has been named president and CEO of Bioreason, of Santa Fe, NM, the company said Tuesday.

 

DePristo comes to the drug discovery informatics company from Amgen, where he was senior director of research and preclinical development information systems. He was also founding president of GeneData's US subsidiary, and also served as vice president of bioinformatics, information technology, and emerging technology at Genome Therapeutics. DePristo received a PhD in theoretical chemistry from the University of Maryland.


 

Agilent Technologies has named May Van as vice president and general manager of the consumables and services business in its Life Sciences and Chemical Analysis group, the company said Tuesday.

 

Van, who joined Hewlett-Packard in 1997, and remained with Agilent when it spun out from its parent in 1999, is being promoted from a position as controller of the consumables and services business. Prior to joining the company, she was director of finance and administration at Integrated Circuit Systems.  She earned a bachelor's of business administration in accounting from Texas Tech University, and an MBA from West Chester University in Pennsylvania.


 

Benitec has named two additional members to its scientific advisory board: David Engelke is director of the University of Michigan program in biomedical sciences, and is also professor of biological chemistry. He is an expert on small RNAs, including those that induce RNA interference, the company said. Cy Stein is head of medical genitourinary oncology and professor of medicine, urology and molecular pharmacology at the Albert Einstein College of Medicine in New York. For the past 15 years, he has been involved with nucleic acid therapy for cancer, and of late, has focused on RNA interference in this area.

 

Both professors will assist the SAB, which is headed by John Rossi of the City of Hope National Medical Center to provide guidance to Benitec in meeting its goal of developing therapeutics using its DNA-directed RNA interference technology, the company said.


 

Karen Moore has been named chief science officer of BioPoint Solutions, the biopharma data management company said last week.

 

Moore was previously a consultant at UK-based Etiologics, and facilitated the company's expansion to the US, BioPoint said. She was a co-founder of Hypnion, a sleep disorder therapeutics firm, and previously held management-level positions with Millennium Pharmaceuticals, which she joined at its founding in 1993.


 

Mark Schwartz has been appointed president and CEO of Bayhill Therapeutics, the Palo Alto, Calif., firm said Monday.

 

Schwartz comes to Bayhill, which is developing therapeutics for autoimmune disease, from Calyx, where he was CEO. Before that, he was chief commercial officer at Trega BioSciences, where he facilitated the company's merger with Lion Bioscience. He has also held management positions at Synteni, Incyte Genomics, and Tripos. Schwartz received a BA in chemistry from Grinnell College and a PhD in biochemistry from Arizona State University.


 

Stuart Kim of Stanford University has won the Ho-Am Prize in medicine for his work on Caenorhabditis elegans developmental genetics, the University said last week.

 

The prize, which carries an honorarium of $90,000, was created to honor Byung-Chull Lee (nicknamed Ho-Am), the founder of Samsung, and is awarded to people of Korean descent who "have contributed to cultural, artistic and social development or furthered the welfare of humanity through distinguished accomplishments in their respective professional fields," according to the university."

 

Kim, who has been at Stanford since 1989, heads up a lab that uses microarrays to analyze the way groups of C. elegans genes act in tandem to control developmental processes and aging within the organism.


 

Roberto Guerciolini has been named senior vice president of development and chief medical officer at Sirna Therapeutics, the company said last week.

 

Guerciolini comes to the Boulder, Colo.-based RNAi therapeutics firm from Millennium Pharmaceuticals, where he was senior director of clinical pharmacology and experimental medicine. Before joining Millennium, Guerciolini served as director of medical research at Roche Global Development and director of pharmacodynamics/international clinical research at Hoffmann-La Roche where he was involved in the filing of regulatory applications for the obesity drug Xenical. Earlier, Guerciolini was associate director of clinical pharmacology/clinical research at Schering-Plough. 

 

Guerciolini received his medical degree from the University of Perugia Medical School in Italy and completed a postdoctoral fellowship in clinical pharmacology at the Mayo Clinic. He also received an executive MBA from the Hass School of Business at the University of California-Berkeley.


 

Ralph Harkins has been named Vice President, Biometrics at the Otsuka Maryland Research Institute, the US clinical research and development arm of Otsuka Pharmaceutical in  Tokyo.

 

Harkins most recently was director, biostatistics and statistical programming, with i3 Data Services in Basking Ridge, NJ. Before that, he was director, biostatistics and clinical data management at Forest Laboratories, and President of the RDH Pharma Group. He also worked at the US Food and Drug Administration for over ten years.

 

Harkins received a PhD in Biostatistics and a Master of Science in Mathematical Statistics from the University of Oklahoma, OU Health Sciences Center, and a BS in Mathematics from Central State University in Edmond, OK.


 

Genstruct has appointed William Ladd as vice president-discovery systems, the  drug discovery company said last week.

 

Ladd was most recently senior sirector of analytic applications at Spotfire. Before joining Spotfire, he was director of bioinformatics methods at Gene Logic. Earlier, he worked in the biological data department at Merck.


 

Joseph "Jay" Mohr has been named president and chief executive officer of Gloucester Pharmaceuticals, the company said last week.

 

Mohr comes to Gloucester, a cancer therapeutics company, from Variagenics, where he was president and chief business officer. Prior to joining Variagenics in 2001, he was vice president of Serono's metabolic endocrinology strategic business unit. He has also served as an executive at Schering-Plough. Mohr received his BA from Vanderbilt University and his MBA from the Wharton School, University of Pennsylvania.


 

Bruce Holm has been appointed director of the Buffalo Center of Excellence in Bioinformatics and Life Sciences of the University at Buffalo, the university said earlier this month.

 

Holm was previously senior vice provost at the University, which is a branch of the State University of New York.


 

James Glover has been named chief financial officer of Beckman Coulter, the company said last month.

 

Glover has held the post of interim CFO since August 2003. He is a 21-year veteran of the company, having joined in 1983 and most recently serving as vice president, controller and chief accounting officer since early 2003. 

 

Glover, a certified public accountant, holds a BS in accounting from California State Polytechnic University, Pomona, and an MBA from Pepperdine University.

 

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.